Takeda submits NDA for alogliptin

Takeda (Tokyo:4502) submitted an NDA to FDA for alogliptin ( SYR-322) to treat Type II diabetes. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor designed to be taken orally once daily. ...